HealthLeaders Media November 17, 2022
A new study says drug companies reduce access to care by limiting 340B community pharmacies.
As 340B payments remain in the spotlight, a new study says drug companies are limiting 340B pricing with community and specialty pharmacies which in turn is having an adverse impact on access to care for patients and communities across the country.
In July, the Supreme Court unanimously ruled that cuts to hospital reimbursement under the 340B drug discount program were unlawful. At the time, the justices said that HHS’ failure to survey hospital costs before enacting the cuts exceed the agency’s authority under the Medicare statute, making the decision to reduce 340B reimbursement unlawful.
The ruling was the culmination of a court battle stretching back...
Today's Sponsors
Today's Sponsor